- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04996121
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
The Safety Tolerability Pharmacokinetic Characteristics and Efficacy of XZP-5955 Tablets in Patients With NTRK or ROS1 Gene Fusion Locally Advanced or Metastatic Solid Tumors in a Single-arm Open-label Multi-center Phase I/II Clinical Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Jingjing Dong
- Phone Number: +86-13811667040
- Email: dongjingjing@xuanzhubio.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Recruiting
- Cancer Hospital Chinese Academy of Medical Sciences
-
Contact:
- Yuankai Shi, Doctor
- Phone Number: +86-13701251865
- Email: syuankaipumc@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects aged ≥18 years old;
- Phase I dose escalation period: Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor, assessed by investigator that no standard therapy exists, or the tumor has relapsed, progressed or was nonresponsive to available therapies, or intolerance, or not suitable to standard therapy at current stage. Priority will be given to patients who have previously documented NTRK or ROS1 gene fusion confirmed by the central laboratory; Phase I dose expansion and Phase II: Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor, patients can provide a written report of pathological diagnosis of NTRK or ROS1 positive tested by qualified laboratory;
- Phase I dose expansion cohort 1 and Phase II cohort 1: locally advanced, or metastatic solid tumor with NTRK gene fusion Phase I dose expansion cohort 2 and Phase II cohort 2: locally advanced, or metastatic NSCLC with ROS1 gene fusion that has progressed to crizotinib and other therapies or was intolerance to crizotinib Phase I dose expansion cohort 3: locally advanced, or metastatic NSCLC with ROS1 gene fusion who have not previously received crizotinib or other therapy.
- phase I dose escalation: at least 1 measurable target lesion according to RECIST version 1.1 Phase I dose expansion and Phase II: at least 1 measurable target lesion according to RECIST version 1.1 (Tumor lesions treated with prior radiation or other local treatment are considered measurable if they show definite progression)
- ECOG PS 0-1
- Life expectancy ≥ 3 months.
Adequate organ function:
Baseline laboratory values fulfilling the following requirements: Absolute neutrophils count (ANC) ≥1.5 × 109/L; Platelets (PLTs) ≥75 × 109/L; Hemoglobin ≥ 85g/L; Serum creatinine≤ 1.5 × ULN, or creatinine clearance ≥50 mL/min/1.73m2(only when serum creatinine>1.5 × ULN); Total serum bilirubin ≤1.5 × ULN; Liver transaminases (AST/ALT) ≤ 2.5 × ULN,≤3× ULN if liver metastases are present or liver cancer patients; Activated Partial Thromboplastin Time≤1.5× ULN;International Normalized Ratio (INR)≤1.5× ULN;
- Eligible patients (male and female) who are fertile must agree to at least use a reliable contraceptive method with partner during the trial and within 90 days from the last dose; Women of childbearing age must have a negative serum pregnancy test within 7 days before the first dose of the trial.
Exclusion Criteria:
Received anti-tumor therapy such as chemotherapy, radiotherapy, biotherapy, endocrine therapy, immunotherapy or other therapy within 4 weeks prior to the first dose of the investigational drug except the following:
Nitroso ureas or mitomycin C within 6 weeks before the first dose of the drug; Oral fluorouracil and small molecule targeted drugs within 2 weeks prior to the first dose of drug or within 5 half life (whichever is longer);
- Received other unmarketed investigational drugs or treatments within 4 weeks prior to the first dose of the investigational drug;
- Major organ surgery (except biopsy) or significant trauma within 4 weeks prior to first dose of the investigational drug or required elective surgery during the trial;
- Adverse reactions to previous antitumor therapy have not recovered to NCI CTCAE 5.0 ≤ grade 1 (except for alopecia, grade 2 peripheral neurotoxicity, stable hypothyroidism after hormone replacement therapy, etc.);
- Inability to swallow drug, or a condition that the investigator judged to severely affect gastrointestinal absorption (eg:Chronic Diarrhea, intestinal obstruction, etc.);
- Cerebral or meningeal metastases with clinical symptoms. The below patients were allowed to be included: those who were asymptomatic, stable, and did not require steroid treatment for more than 4 weeks prior to the start of study treatment (if the cerebral metastases had undergone radiotherapy or/and surgery, radiotherapy and surgery should be at least 1 month prior to the first dose) ;
- Known active infections and currently need intravenous anti-infective therapy;
- History of immune deficiencies, including positive HIV antibody tests;
- Active Hepatitis B (HBsAg and/or HBcAb positive with HBV-DNA > 500IU/ml) or hepatitis c virus infection (positive test results of anti-HCV with positive HCV-RNA );
- Known interstitial lung disease (except for radioactive pulmonary fibrosis that does not require steroid therapy);
- History of serious cardiovascular disease;
- Pregnant or lactating women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: XZP-5955 tablets
|
Phase I dose escalation: For each dose cohort, XZP-5955 tablet will be administered orally, single dose for day 1 and then from day 4, administered for continuous cycles of 21 consecutive days for each cycle Phase I dose expansion: XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle. Some patients for PK sample collection, the drug will be administered single dose for day 1, then from day 4, administered for continuous cycles of 21 consecutive days for each cycle Phase II: XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose (MTD) (Phase I dose escalation)
Time Frame: 24days following first dose of XZP-5955
|
Determine MTD of XZP-5955
|
24days following first dose of XZP-5955
|
Number of patients with adverse events (Phase I dose escalation)
Time Frame: within 30 days from last dose
|
Incidence of AE as assessed by CTCAE 5.0
|
within 30 days from last dose
|
Overall Response Rate (ORR) by Blinded Independent Central Review (BICR) (Phase I dose expansion and phase II)
Time Frame: 2 to 3 years after first dose of XZP-5955
|
Per RECIST v1.1 as assessed by BICR
|
2 to 3 years after first dose of XZP-5955
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I: Area under the concentration versus time curve of XZP-5955 in plasma (AUC)
Time Frame: Pre-dose, up to 72h after drug on Day 1;pre-dose on day 8, day 15 of cycle 1, , pre-dose and up to 12h after drug on day21 of cycle 1;pre-dose on day1 of cycle 2 and 3
|
To determine the area under the plasma concentration time curve (AUC) of XZP-5955
|
Pre-dose, up to 72h after drug on Day 1;pre-dose on day 8, day 15 of cycle 1, , pre-dose and up to 12h after drug on day21 of cycle 1;pre-dose on day1 of cycle 2 and 3
|
Phase I: Maximum plasma concentration (Cmax) of XZP-5955
Time Frame: Up to 72 hours post dose of Day 1
|
To determine the maximum plasma concentration (Cmax) of XZP-5955
|
Up to 72 hours post dose of Day 1
|
Phase I: Oral clearance (CL/F) of XZP-5955
Time Frame: Pre-dose, up to 72h after drug on Day 1;pre-dose on day 8, day 15 of cycle 1, pre-dose and up to 12h after drug on day21 of cycle 1;pre-dose on day1 of cycle 2 and 3
|
To determine the oral clearance (CL/F) of XZP-5955
|
Pre-dose, up to 72h after drug on Day 1;pre-dose on day 8, day 15 of cycle 1, pre-dose and up to 12h after drug on day21 of cycle 1;pre-dose on day1 of cycle 2 and 3
|
objective response rate (ORR) (Phase I and Phase II)
Time Frame: 2 to 3 years after first dose of XZP-5955
|
To determine the preliminary objective response rate (ORR) by investigator
|
2 to 3 years after first dose of XZP-5955
|
Progression free survival (PFS) (Phase I and Phase II)
Time Frame: 2 to 3 years after first dose of XZP-5955
|
To determine the PFS by BICR and investigator
|
2 to 3 years after first dose of XZP-5955
|
Duration of response (DOR) (Phase I and Phase II)
Time Frame: 2 to 3 years after first dose of XZP-5955
|
To determine the DOR by BICR and investigator
|
2 to 3 years after first dose of XZP-5955
|
Disease control rate (DCR) (Phase I and Phase II)
Time Frame: 2 to 3 years after first dose of XZP-5955
|
To determine the DOR by BICR and investigator
|
2 to 3 years after first dose of XZP-5955
|
Clinical benefit rate (CBR) (Phase I and Phase II)
Time Frame: 2 to 3 years after first dose of XZP-5955
|
To determine the CBR by BICR and investigator
|
2 to 3 years after first dose of XZP-5955
|
Time to response (TTR) (Phase I and Phase II)
Time Frame: 2 to 3 years after first dose of XZP-5955
|
To determine the TTR by BICR and investigator
|
2 to 3 years after first dose of XZP-5955
|
Death of response (DpR) (Phase I and Phase II)
Time Frame: 2 to 3 years after first dose of XZP-5955
|
To determine the DpR by BICR and investigator
|
2 to 3 years after first dose of XZP-5955
|
Overall survival (OS) (Phase I expansion period and Phase II)
Time Frame: 2 to 3 years after first dose of XZP-5955
|
To determine the OS
|
2 to 3 years after first dose of XZP-5955
|
Intracranial objective response rate (Phase I expansion period and Phase II)
Time Frame: To determine the intracranial ORR
|
2 to 3 years after first dose of XZP-5955
|
To determine the intracranial ORR
|
Number of patients with adverse events ((Phase I dose expansion and Phase II)
Time Frame: within 30 days from last dose
|
Incidence of AE as assessed by CTCAE 5.0
|
within 30 days from last dose
|
Pop PK of XZP-5955 and its metabolite (Phase II)
Time Frame: pre-dose, Tmax on Day1, pre-dose on day 8 of cycle 1, pre-dose on day 1 of Cycle 2, Tmax,ss on Day 1 of cycle 2, pre-dose on day 1 of cycle 3
|
To determine the PopPK characteristics of XZP-5955
|
pre-dose, Tmax on Day1, pre-dose on day 8 of cycle 1, pre-dose on day 1 of Cycle 2, Tmax,ss on Day 1 of cycle 2, pre-dose on day 1 of cycle 3
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- XZP-5955-1001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced or Metastatic Solid Tumors
-
University Medical Center GroningenActive, not recruiting
-
Merck KGaA, Darmstadt, GermanyCompletedLocally Advanced or Metastatic Solid TumorsHungary
-
Hospices Civils de LyonUnknownMetastatic or Locally Advanced Solid TumorsFrance
-
Sichuan Baili Pharmaceutical Co., Ltd.Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.Not yet recruitingLocally Advanced or Metastatic Solid TumorsChina
-
Avistone Biotechnology Co., Ltd.Zhejiang Cancer Hospital; Henan Cancer Hospital; Hunan Cancer Hospital; Peking... and other collaboratorsRecruitingLocally Advanced or Metastatic Solid TumorsChina
-
TYK Medicines, IncRecruitingLocally Advanced or Metastatic Solid TumorsChina
-
Bio-Thera SolutionsRecruitingLocally Advanced or Metastatic Solid TumorsChina
-
Chugai PharmaceuticalRecruitingLocally Advanced or Metastatic Solid TumorsUnited States, Japan
-
Chugai PharmaceuticalRecruitingLocally Advanced or Metastatic Solid TumorsUnited States, Japan
-
Pierre Fabre MedicamentTerminatedLocally Advanced or Metastatic Solid TumorsFrance, Spain
Clinical Trials on XZP-5955 tablets
-
Xuanzhu Biopharmaceutical Co., Ltd.RecruitingROS1 Rearrangement Non-small Cell Lung Cancer | ALK Rearrangement Non-small Cell Lung CancerChina
-
Xuanzhu Biopharmaceutical Co., Ltd.RecruitingNonalcoholic Steatohepatitis (NASH)China
-
Xuanzhu Biopharmaceutical Co., Ltd.Not yet recruiting
-
Xuanzhu Biopharmaceutical Co., Ltd.Not yet recruiting
-
Xuanzhu Biopharmaceutical Co., Ltd.Not yet recruiting
-
Xuanzhu Biopharmaceutical Co., Ltd.Recruiting
-
Sihuan Pharmaceutical Holdings Group Ltd.UnknownAdvanced Breast Cancer | Metastasis Solid TumorsChina
-
Xuanzhu Biopharmaceutical Co., Ltd.Not yet recruiting
-
Sihuan Pharmaceutical Holdings Group Ltd.TerminatedNon Small Cell Lung CancerChina
-
Xuanzhu Biopharmaceutical Co., Ltd.Not yet recruitingHealthy VolunteersChina